The potent suppressive effects of dual TORC1/TORC2 inhibitors on BCR-ABL-transformed cells, have raised the possibility that such agents may have activity in other leukemias and prompted us to perform additional studies to examine the spectrum of the antileukemic properties of OSI-027 in AML. Here, CRTC2 is linked to acute myeloid leukemia.